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Abstract
In the last four years, Genome-Wide Association Studies (GWAS) have identified sixteen low-penetrance polymorphisms on
fourteen different loci associated with colorectal cancer (CRC). Due to the low risks conferred by known common variants,
most of the 35% broad-sense heritability estimated by twin studies remains unexplained. Recently our group performed a
case-control study for eight Single Nucleotide Polymorphisms (SNPs) in 4 CRC genes. The present investigation is a follow-
up of that study. We have genotyped six SNPs that showed a positive association and carried out a meta-analysis based on
eight additional studies comprising in total more than 8000 cases and 6000 controls. The estimated recessive odds ratio for
one of the SNPs, rs3219489 (MUTYH Q338H), decreased from 1.52 in the original Swedish study, to 1.18 in the Swedish
replication, and to 1.08 in the initial meta-analysis. Since the corresponding summary probability value was 0.06, we decided
to retrieve additional information for this polymorphism. The incorporation of six further studies resulted in around 13000
cases and 13000 controls. The newly updated OR was 1.03. The results from the present large, multicenter study illustrate
the possibility of decreasing effect sizes with increasing samples sizes. Phenotypic heterogeneity, differential environmental
exposures, and population specific linkage disequilibrium patterns may explain the observed difference of genetic effects
between Sweden and the other investigated cohorts.
Citation: Picelli S, Lorenzo Bermejo J, Chang-Claude J, Hoffmeister M, Ferna´ndez-Rozadilla C, et al. (2013) Meta-Analysis of Mismatch Repair Polymorphisms
within the Cogent Consortium for Colorectal Cancer Susceptibility. PLoS ONE 8(9): e72091. doi:10.1371/journal.pone.0072091
Editor: Nathan A. Ellis, University of Illinois at Chicago, United States of America
Received January 10, 2013; Accepted July 6, 2013; Published September 6, 2013
Copyright:  2013 Picelli et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
PLOS ONE | www.plosone.org 1 September 2013 | Volume 8 | Issue 9 | e72091
Funding: The authors are grateful to: the Spanish National Genotyping Center (CEGEN-ISCIII)-USC and the UPF nodes, as well as the Institutional Tumor Bank of
Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. The work was carried out (in part) at the Esther Koplowitz Centre, Barcelona. This study was supported by
Instituto de Salud Carlos III, Spanish Ministry of Health, (grants FIS PI08-1635 and PS09-1037, VM); Cancer Research UK Programme Grant (C348/A12076) and a Centre
Grant from the CORE Charity (MD); CZ:GA CR:GAP304/10/1286 and CZ:GA CR:GA310/07/1430 (PV); Hunter Medical Research Institute research grant and Priority
Research Centre for Information Based Medicine (RS); German Research Council, German Federal Ministry of Research and Education (HB, HV); Baden Wu¨rttemberg
State Ministry of Research, Science and Arts (HB); Fondo de Investigacio´n Sanitaria/FEDER (08/0024, 08/1276, PS09/02368, 11/00219, 11/00681); Instituto de Salud
Carlos III (Accio´n Transversal de Ca´ncer), Xunta de Galicia (RHI07/04 and 08CSA005208PR); Ministerio de Ciencia e Innovacio´n (SAF2010-19273); Asociacio´n Espan˜ola
contra el Ca´ncer (Fundacio´n Cientı´fica y Junta de Barcelona); Fundacio´ Olga Torres (CRP), and FP7 CHIBCHA Consortium (AC and SCB); Fondo de Investigacio´n
Sanitaria (CP 03-0070 to SCB and PS09/02368 to CFR). CIBERehd and CIBERER are funded by the Instituto de Salud Carlos III. JLB is partially supported by a grant of the
Deutsche Forschungsgemeinschaft (DFG, SFB/TRR77, project Z2). LL is supported by a grant from National Cancer Institute R01 CA136726. SB, JH, WvS and CS were
supported by the German Ministry for Education and Research through the German National Genome Research Network (NGFNplus) Colon Cancer Network (CCN). The
funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: simone.picelli@licr.ki.se
. These authors contributed equally to this work.
" Membership of The EPICOLON Consortium is provided in the Acknowledgments.
Introduction
In recent years low-risk common alleles have attracted
increasing attention in the search for the ‘‘missing heritability’’
in colorectal cancer (CRC). It concerns the part of heritability that
cannot be explained by mutations in already known high-risk
genes but should, according to twin studies, account for about
35% [1]. Known high-penetrance germline mutations in CRC
genes contribute for less than 6% of the observed cases [2].
Therefore, much of the remaining inherited variation in genetic
susceptibility is probably due to multiple low-penetrance variants,
both common and rare.
To date sixteen common variants have been identified through
large multi-centre genome-wide association studies (GWAS) [3].
Taken together, however, they only explain a small proportion of
familial CRC cases. Although the risk associated with each of these
variants is modest, they contribute to the disease burden due to
their high frequency in the population and the possibility of acting
in concert with each other, which may increase the individual’s
risk of developing CRC [4].
Against this background, a few years ago we attempted to assess
the role of eight SNPs in four already known CRC genes (APC,
MLH1, MSH6 and MUTYH) through a case-control association
study in the Swedish population [5]. These 8 SNPs had been
previously studied, but their pathogenicity was unknown and they
were assumed to constitute polymorphisms. In our first study
several positive associations were detected but, due to limited
sample size (1785 cases and 1722 controls) [5], the results needed
to be validated in a follow-up study.
The present study was an initiative of the COGENT
consortium [4,6], where different groups offered to extend the
genotyping to other non-Swedish cohorts for SNPs showing
statistically significant associations in at least one analysis of the
original study. This restricted the analysis to six out of the original
eight SNPs.
Materials and Methods
Ethics statement
Collection of blood samples and clinical information from
patients and controls was obtained with informed consent in
accordance with the tenets of the Declaration of Helsinki. All
participants gave written informed consent to take part in the
study. The study was undertaken in accordance with the Swedish
legislation of ethical permission (2003:460) and approved by the
Stockholm Regional Research Ethical Committee (Dnr 2002:489).
Mutation screening
Six SNPs in four different CRC genes were included in the
analysis: rs459552:T.A (APC D1822V), rs1799977:A.G (MLH1
I219V), rs1800932:A.G (MSH6 P92P), rs1800935:T.C (MSH6
D180D), rs3219484:G.A (MUTYH V22M) and rs3219489:G.C
(MUTYH Q338H). MUTYH Q338H corresponds to Q324H in
our first study [5]. The SNP nomenclature was modified to meet
the Human Genome Variation Society’s (HGVS) guidelines,
which recommends the use of a reference sequence representing
the largest theoretically known transcript. For MUTYH this
corresponds to NM_001128425.1 and NP_001121897.1 for
mRNA and protein, respectively [7,8,9].
Subjects
Details regarding the number of cases and controls in all
fourteen studies are summarized in Table S1. One SNP, rs459552
(APC D1822V), was genotyped in seven studies, for a total of 8654
cases and 7731 controls. Four SNPs, rs1799977 (MLH1 I219V),
rs1800932 (MSH6 P92P), rs1800935 (MSH6 D180D) and
rs3219484 (MUTYH V22M) were genotyped in 8 studies for a
total of 8308 cases and 7434 controls. The SNP with rs number
3219489 (MUTYH Q338H) was genotyped in 13 cohorts for a
total of 12902 cases and 14602 controls.
For all the subjects genomic DNA was extracted from
peripheral blood by standard procedures. Additional information
regarding localization of the tumor, age at diagnosis, gender and
ethnicity was retrieved whenever possible. Out of 5770 controls
with ethnicity information, 5647 were of Caucasian origin, the rest
being mostly African American.
Genotyping
In studies 1, 5, 6, 7, 8, 9 and 10 SNPs were genotyped using the
TaqMan SNP Genotyping Assay (Applied Biosystem, Foster City,
CA). Genotyping in study 2 and 12 (controls only) was carried out
by using the KASPar chemistry of the K-bioscience (Hoddesdon,
Herts, UK) (http://www.kbioscience.co.uk/reagents/
KASP_manual.pdf), which is a competitive allele-specific PCR
SNP genotyping system that uses FRET quencher cassette oligos.
Study 3 genotyped with the MassARRAY (Sequenom Inc., San
Diego, USA) technology. Study 4 genotyped by means of
fluorescent hybridization probe melting curves using the Light
Cycler instrument (Roche). Study 11 genotyped using Illumina
HumanHap 550 Bead Arrays. Study 12 was genotyped by Sanger
sequencing (cases only). Studies 13 and 14 were genotyped using
Illumina HumanHap300 and Illumina HumanHap240S.
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Statistical analysis
Deviations of observed genotype frequencies in controls from
those expected under Hardy-Weinberg equilibrium were assessed
by x2 tests. Risks of CRC associated with genotypes were
compared by odds ratios (ORs) with corresponding confidence
intervals (CIs) based on logistic regression. Study heterogeneity
was summarized using a Mantel–Haenszel test but we assumed
that the studies were random samples from a general population
and used a random effect model to summarize OR estimates
under dominant, recessive and additive penetrance models in the
meta-analyses. Results were represented by forest plots as follows:
confidence intervals for each individual study were indicated by
horizontal lines, single ORs by squares and summary estimates by
diamonds with horizontal limits at confidence limits and width
inversely proportional to the standard error. Meta-analyses were
performed using the package rmeta in the free software environ-
ment for statistical computing R.
Results
The distribution of the genotypes in controls did not deviate
from Hardy-Weinberg equilibrium in any study. Mantel-Haenszel
tests identified study heterogeneity for rs1800932 (MSH6 P92P)
under recessive and additive penetrance, with p-values equal to
0.04 and 0.03, respectively (Table S2). This does not constitute a
major issue since this SNP showed no differences between the
genotype distributions of cases and controls either in single studies
or in the global analysis. Study heterogeneity was not found for
any other SNP. Genotyping results for the 6 SNPs based on studies
1–8 are presented in Table S2.
The only SNP that was marginally significant in the meta-
analysis was rs3219489 (MUTYH Q338H), both under a recessive
model (summary OR = 1.08, 95% CI 1.00 to 1.17; p = 0.05) and
assuming additive allelic effects (summary OR = 1.07, 95% CI
1.00 to 1.14; p = 0.06). We ascribe the combined result mainly to
the Swedish study, with individual ORs of 1.18 (95% CI = 1.01–
1.38, recessive model) and 1.19 (95% CI = 1.05–1.35, additive
model) (Table S2). The goodness of fit was slightly better for the
recessive than for the additive model, and the recessive and
additive models clearly outperformed the dominant model.
In an attempt to validate the findings under recessive
inheritance, we set up collaborations with additional groups and
requested to genotype rs3219489 in their cohorts. In the end,
additional 4234 cases and 6800 controls were included, adding up
to a total of 12232 cases and 13380 controls (Table S3).
We updated the meta-analysis once more considering all
samples regardless of tumor localization as well as stratifying
them for colon and rectal tumors. As shown in Table S4, data
were available for 4573 colon and 1774 rectal cancer cases.
Results from the updated meta-analyses are presented in Figure 1.
The new summary OR for colorectal cancer was 1.03 (95% CI
0.97 to 1.10, probability value 0.25) (Figure 1A). The summary
OR was practically identical after adjustment for age and gender
OR = 1.03 (95% CI 0.93 to 1.13). Study heterogeneity was not
noticed (P = 0.29, data not shown). The combined OR for colon
cancer was 1.07 (95% CI 0.99 to 1.16, probability values 0.09
(OR = 1) and 0.37 (study homogeneity) (Figure 1B) and for rectal
cancer was 1.06 (95% CI 0.94 to 1.19, probability values 0.37
(OR = 1) and 0.31 (study homogeneity)) (Figure 1C).
Discussion
In the present investigation we performed a case-control
association study for six out of eight previously investigated SNPs
[5]. For five of them, rs459552 (APC D1822V), rs1799977 (MLH1
I219V), rs1800932 (MSH6 P92P), rs1800935 (MSH6 D180D) and
rs3219484 (MUTYH V22M) samples were retrieved from eight
additional studies totaling 8308 cases and 7434 controls. For the
sixth SNP, rs3219489 (MUTYH Q338H), which was selected
based on promising results from two samples of Swedish origin
(study 8 in the present manuscript and reference [5]), we set up an
even larger replication dataset comprising 14 different studies with
a total of 12232 cases and 13380 controls.
For all SNPs included in the analysis we were unable to confirm
the associations with CRC risk found in the Swedish population.
In particular, the recessive ORs of CRC for rs3219489 decreased
from 1.52 in the original Swedish study to 1.18 in the Swedish
replication cohort, to 1.08 (95% CI 1.00 to 1.17) in the first meta-
analysis and to 1.03 (95% CI 0.97 to 1.10) in the updated meta-
analysis (Table S2). The summary ORs in the extended meta-
analyses were 1.07 (95% CI 0.99 to 1.16) for colon cancer and
1.06 (95% CI 0.94 to 1.19) for rectal cancer, in contrast with
results based on Swedish samples. The updated meta-analysis had
statistical power of 99% to detect a recessive OR of 1.52 and a
power of 89% to detect a recessive OR of 1.18 (Type I error rate
5% and prevalence of CC genotypes among controls 5.6%).
Biological plausibility was also existent. MUTYH Q338H is
interesting because it represents a missense change in the
MUTYH protein, which is involved in the base excision repair
(BER) pathway. A common product of oxidative damage to 29-
deoxyguanosine is 7,8-dihydro-8-oxo-29-deoxyguanosine (OG)
[10,11]. In mammalian cells OG has been shown to be highly
mutagenic and leading to an increased rate of GRT transversions,
due to its miscoding properties that cause a mispairing with an
adenine during DNA replication to form a stable OG:A mismatch
[11,12]. The BER pathway plays an important role in repairing
this type of DNA damage through the action of the mutY homolog
MUTYH, in concert with OGG1 and MTH1 [11,13]. It is well
established that biallelic mutations in MUTYH gene introduce G:C
to T:A transversions also in the adenomatous polyposis coli (APC)
gene, leading to genomic instability and abnormal and dis-
regulated cell proliferation in the colonic epithelium [14,15].
Patients with two mutations in the MUTYH gene develop the
MUTYH-associated polyposis (MAP) syndrome [13].
To date, 85 different MAP-associated mutations have been
found [16], scattered throughout the entire length of the protein,
but only 3 (including Q338H) map within putative protein
interaction domains as revealed by the recently solved crystal
structure of hMUTYH [17]. It is tempting to speculate that
Q338H might affect this protein-protein interaction, but addi-
tional experimental support is warranted.
The contrasting results on rs3219489 and its association with
CRC risk in the Swedish versus other populations might suggest
that the effect of this variant is specific for the Swedish population
or not large enough in the other populations to be detected with
the present sample size. For example, the statistical power of the
updated meta-analysis was only 43% to detect a recessive OR of
1.10 (Type I error rate 5% and prevalence of CC genotypes
among controls 5.6%). A closer look at the data actually shows that
one of the German cohorts (ESTHER) gave results in agreement
with our Swedish cohorts, with OR = 1.36 (95% CI 1.00 to 1.86)
for colorectal cancer (Figure 1A) and OR = 1.61 (95% CI 1.08 to
2.40) for rectal cancer (Figure 1C). This is likely a spurious result
due to the small size of that cohort (318 cases and 365 controls).
On the other hand, in agreement with Swedish results,
rs3219489 has also been shown to be associated with CRC risk
in three independent studies in the Japanese population [18,19,20]
and among African-Americans (Yuan et al., 2nd InSiGHT
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meeting, Yokohama, Japan, unpublished) even though all these
studies have a limited sample size and the results need further
validation.
It is also possible that rs3219489 represents a risk-associated
variant in the Swedish population in combination with environ-
mental factors in the broad sense. For example, screening
programs for CRC in Sweden could result in a diagnosis earlier
in life, thus inflating the ORs estimated in Sweden. Another
alternative is that the polymorphism is in linkage disequilibrium
with other unidentified causal variants. The marker and the causal
variant could be located on the same risk haplotype in the Swedish
population and on different haplotypes in other populations.
Independently of the unknown reason for replication failure, the
results from the present study clearly illustrate the possibility of
Figure 1. Forest plots with observed odds ratios and 95% confidence intervals for rs3219489 (MUTYH Q338H) under a recessive
penetrance model in colorectal cancer (A), colon cancer only (B) and rectal cancer only (C).
doi:10.1371/journal.pone.0072091.g001
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decreasing effect sizes with increasing collections of individuals, a
phenomenon well-known in the field of genetic epidemiology
denominated the winner’s curse [21]. It should be kept in mind
that this outcome is rather expected in association studies, in
particular those dealing with regionally heterogeneous complex
diseases.
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